This patent, exclusively licensed from the Massachusetts General Hospital, provides FluoroPharma with additional patent claims that cover imaging of atherosclerotic plaque inflammation and rupture.
Kundakovic, president of FluoroPharma, said: “Our broad technology platform continues to provide FluoroPharma with the ability to develop effective cardiovascular imaging agents for PET market.”